| Page 12 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Author(s): 
Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U
Primary Author: 
Sekeres MA
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Nov 2024
Bone Marrow Disease(s): 

Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists

Author(s): 
Blankstein AR, Choi N, Mozessohn L, Sanford D, Paulson K, Rimmer E, Houston DS, Lother SA, Mendelson A, Garland A, Zarychanski R, Hay AE, Buckstein R, Houston BL
Primary Author: 
Blankstein AR
Journal Title: 
Annals of Hematology
Original Publication Date: 
Nov 2024

Bone Marrow Disease(s): 

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study

Author(s): 
Andritsos LA, McBride A, Tang D, Barghout V, Zanardo E, Song R, Huynh L, Yenikomshian M, Makinde AY, Hughes C, Hanna KS, Patel K
Primary Author: 
Andritsos LA
Journal Title: 
Leukemia Research
Original Publication Date: 
Nov 2024

Bone Marrow Disease(s): 

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Author(s): 
Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM
Primary Author: 
Bidikian A
Journal Title: 
Expert Review of Anticancer Therapy
Original Publication Date: 
Nov 2024

Introduction: 

Bone Marrow Disease(s): 

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

Author(s): 
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT,
Primary Author: 
Komrokji RS
Journal Title: 
Lancet Haematology
Original Publication Date: 
Oct 2024

The WHO and International Consensus Classification 2022 classifications of

Bone Marrow Disease(s): 

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

Author(s): 
Griffin M, Gandhi S, Kelly RJ, Munir T, Trikha R, Hicks E, Jain D, Ogawa M, Yu J, Muus P, Kulasekararaj AG
Primary Author: 
Griffin M
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2024
Bone Marrow Disease(s): 

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment

Author(s): 
Kokoris S, Polyviou A, Evangelidis P, Grouzi E, Valsami S, Tragiannidis K, Gialeraki A, Tsakiris DA, Gavriilaki E
Primary Author: 
Kokoris S
Journal Title: 
International Journal of Molecular Sciences
Original Publication Date: 
Nov 2024

Bone Marrow Disease(s):